Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The p16 protein plays an important role in the transition of cells into the G1 phase of the cell cycle. We have studied the prevalence of p16 protein expression in breast carcinomas in a prospective series of 368 invasive and 52 non-invasive malignancies, as well as in 88 locally recurring tumours and three tumour cell lines. p16 protein expression was evaluated immunohistochemically on paraffin sections using monoclonal and polyclonal anti-p16 antibodies, and by immunoblotting of tumour cell suspensions. Tumour cell lines were also subjected to polymerase chain reaction-single strand polymorphism (PCR-SSCP) analysis and direct DNA sequencing. The results were compared with established prognostic parameters, DNA flow cytometry and p53 protein expression. In 33 (9%) invasive and two (4%) intraductal carcinomas, a cytoplasmic accumulation of the p16 protein was seen. These cases were characterized by poor histological grade of differentiation, loss of of oestrogen receptors and progesterone receptors and frequent overexpression of the p53 protein. In addition, breast carcinomas with aberrant p16 expression demonstrated a high proliferative activity, with median S-phase fractions 74% higher than in the control group and the median Ki67 fractions elevated to 75%. A genetic alteration of the p16 gene was not detectable in three analysed cell lines with cytoplasmic p16 expression applying PCR-SSCP and direct DNA sequencing. These results indicate that cytoplasmic accumulation of the p16 protein identifies a subset of highly malignant breast carcinomas with accelerated tumour proliferation and other unfavourable parameters in breast cancer. The described protein accumulation is apparently not caused by an alteration of the p16 gene.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 1×
“All tumours were classified according to the AFIP classification for brast carinomas (Rosen and Oberman, 1992) and staged acoding to the TNM system (UICC, 1992) (for details see Table 1).”
MethodA cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition
Koh, J., Enders, G. H., David Dynlacht, B., & Harlow, E. (1995) · Nature · doi:10.1038/375506a0 · Cited by 516
Cited by
Romagosa, C., Simonetti, S., López-Vicente, L., Mazo, A., Lleonart, M. E., Castellvi, J., & Ramon y Cajal, S. (2011) · Oncogene · doi:10.1038/onc.2010.614 · Cited by 509
Melk, A., Schmidt, B. M. W., Takeuchi, O., Sawitzki, B., Rayner, D. C., & Halloran, P. F. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00438.x · Cited by 362
“In some publications cytoplasmic p16INK4a staining has been shown to be associated with more aggressive tumors [43, 44]; others suggest that it has no specific significance [45].”
BackgroundHerschkowitz, J. I., He, X., Fan, C., & Perou, C. M. (2008) · Breast Cancer Research · doi:10.1186/bcr2142 · Cited by 255
Gauthier, M. L., Berman, H. K., Miller, C., Kozakeiwicz, K., Chew, K., Moore, D., Rabban, J., Chen, Y. Y., Kerlikowske, K., & Tlsty, T. D. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.017 · Cited by 214
Melk, A., Schmidt, B. M. W., Vongwiwatana, A., Rayner, D. C., & Halloran, P. F. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.00846.x · Cited by 154
Metadata
- Authors
- Emig, R., Magener, A., Ehemann, V, Meyer, A., Stilgenbauer, F., Volkmann, M., Wallwiener, D., & Sinn, H.
- Venue
- British Journal of Cancer
- Published
- 1998-12
- Volume
- 78
- Issue
- 12
- Pages
- 1661-1668
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1983269088
- Cited by
- 97
- References
- 5
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. https://app.cochat.ai/papers/10.1038/bjc.1998.739
- The paper
- Emig, R., Magener, A., Ehemann, V, Meyer, A., Stilgenbauer, F., Volkmann, M., Wallwiener, D., & Sinn, H. (1998). Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. British Journal of Cancer. https://doi.org/10.1038/bjc.1998.739
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.